Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Nov 24.
Published in final edited form as: Eur J Cancer Prev. 2013 May;22(3):10.1097/CEJ.0b013e3283592cef. doi: 10.1097/CEJ.0b013e3283592cef

Association of body mass index and risk of death from pancreas cancer in Asians: findings from the Asia Cohort Consortium

Yingsong Lin 1, Rong Fu 2, Eric Grant 3, Yu Chen 4, Jung Eun Lee 5, Prakashi C Gupta 6, Kunnambath Ramadas 7, Manami Inoue 8, Shoichiro Tsugane 8, Yu-Tang Gao 9, Akiko Tamakoshi 10, Xiao-Ou Shu 11, Kotaro Ozasa 3, Ichiro Tsuji 12, Masako Kakizaki 12, Hideo Tanaka 13, Chien-Jen Chen 14,15, Keun-Young Yoo 16, Yoon-OK Ahn 16, Habibul Ahsan 17,18,19,20, Mangesh S Pednekar 6, Catherine Sauvaget 21, Shizuka Sasazuki 8, Gong Yang 11, Yong-Bing Xiang 9, Waka Ohishi 22, Takashi Watanabe 12, Yoshikazu Nishino 23, Takeshi Suzuki 13, San-Lin You 14,24, Sue K Park 25, Dong-Hyun Kim 26, Faruque Parvez 27, Betsy Rolland 2, Dale McLerran 2, Rashmi Sinha 28, Paolo Boffetta 29,30, Wei Zheng 11, Mark Thornquist 2, Ziding Feng 2, Daehee Kang 16, John D Potter 2,31
PMCID: PMC3838869  NIHMSID: NIHMS525647  PMID: 23044748

Abstract

Objective

We aimed to examine the association between BMI and the risk of death from pancreas cancer in a pooled analysis of data from the Asia Cohort Consortium.

Methods

The data for this pooled-analysis included 883,529 men and women from 16 cohort studies in Asian countries. Cox proportional-hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for pancreas cancer mortality in relation to BMI. Seven predefined BMI categories (<18.5, 18.5–19.9, 20.0–22.4, 22.5–24.9, 25.0–27.4, 27.5–29.9, ≥30) were used in the analysis, with BMI of 22.5–24.9 serving as the reference group. The multivariable analyses were adjusted for known risk factors, including age, smoking, and history of diabetes.

Results

We found no statistically significant overall association between each BMI category and risk of death from pancreas cancer in all Asians, and obesity was unrelated to mortality risk in both East Asians and South Asians. Age, smoking, and history of diabetes did not modify the association between BMI and risk of death from pancreas cancer. In planned subgroup analyses among East Asians, an increased risk of death from pancreas cancer among those with a BMI<18.5 was observed for individuals with a history of diabetes; HR = 2.01(95%CI: 1.01–4.00) (p for interaction=0.07).

Conclusion

The data do not support an association between BMI and risk of death from pancreas cancer in these Asian populations.

Keywords: body mass index, insulin resistance, obesity, overweight, pancreatic cancer

Introduction

Pancreas cancer is one of the most aggressive malignancies in humans, with an all-stage 5-year survival of less than 10% [1]. According to Globocan, pancreas cancer was diagnosed in an estimated 107,810 Asian men and women in 2008 and a similar number (98,214) died from the disease [2]. Although this cancer used to be rare in Asia, incidence rates in East Asia have been increasing over the past decades and now approximate those in Europe and North America [2].

Epidemiologic studies have clearly shown that cigarette smoking and longstanding type-II diabetes are associated with increased risk of pancreas cancer [34]. There is also mounting evidence for an association with being overweight or obese [5]. Statistically significant, positive associations were observed in large cohort studies conducted in Western countries [68], and corroborated in at least 4 meta-analyses [912] and 3 pooled analyses [1315]. The mechanisms by which obesity confers increased risk are not well understood. Because obesity is closely related to insulin resistance and hyperinsulinemia and because high fasting serum glucose and insulin levels have been shown to predict pancreas cancer risk in diverse ethnic populations [1618], insulin resistance and hyperinsulinemia are thought to play a central role [19].

Based on a review of the literature, the World Cancer Research Fund concluded that the evidence that greater body fatness is a cause of pancreas cancer is convincing [20]. It is worth noting, however, that this conclusion was based on the summary of findings mainly from cohort studies conducted in Western countries; very few Asian studies were included. The observed differences in body fat distribution, genetic predisposition to obesity, and background lifestyle factors between Caucasians and Asians [21] suggest that the association between BMI and pancreas cancer may differ by ethnic group. To date, 4 cohort studies have examined the BMI-pancreas cancer associations in Asians, but the results have been inconsistent and inconclusive [2225].

Given the plausible mechanisms underlying an obesity-pancreas cancer association and the paucity of data from Asian populations, we examined the relationship in a pooled analysis of data from the Asia Cohort Consortium (ACC), which involved 883,529 men and women. This pooled analysis allowed us to estimate the risk of death from pancreas cancer in relation to finer BMI categories than would be feasible within any single study.

Methods

Study population

ACC is a consortium of cohort studies in Asian countries, the primary purpose of which is to explore the relationship among genetics, environmental exposures, and the etiology of disease. The details concerning the initiation and conduct of the ACC have been described elsewhere [26, 27]. The ACC has recruited 19 cohorts to date. Sixteen cohorts provided information on death from pancreas cancer during follow-up as well as data on BMI, cigarette smoking, and history of diabetes at baseline; these cohorts were included in this pooled analysis. Of these cohorts, 8 are in Japan, 2 in China, 1 in Taiwan, 2 in Korea, 2 in India, and 1 in Bangladesh. For this pooled analysis, we excluded 50,421 individuals with missing data on age, sex, cigarette smoking, and/or BMI. Also excluded were individuals who had a prior cancer diagnosis at baseline, those who had a BMI>50 or <15, and those with invalid or missing data on survival. The final study population included 799,542 subjects.

This study was approved by the ethics committee overseeing each of the participating cohort studies and by the IRB at the Fred Hutchinson Cancer Research Center.

Exposure measurement and outcome ascertainment

In the majority of the ACC participating cohorts, height and weight at baseline were both self-reported. Outcomes for pancreas cancer mortality were ascertained from the causes of death recorded on death certificates. Information on cigarette smoking, history of diabetes, and other lifestyle factors was collected at baseline.

Statistical analysis

We quantified the association between BMI and risk of death from pancreas cancer based on a meta-analysis of individual data from each cohort and a pooled analysis of aggregated data from all participating cohorts. For the meta-analysis, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for each cohort, and a random-effects model was adopted to calculate a summary HR by combining cohort-specific HRs [28]. BMI was modeled categorically, using 7 predefined BMI categories (<18.5, 18.5–19.9, 20.0–22.4, 22.5–24.9, 25.0–27.4, 27.5–29.9, ≥30). Individuals with BMIs of 22.5–24.9 served as the reference category because this BMI category has been shown to be associated with the lowest risk of all-cause mortality in East Asian populations [2931]. Between-study heterogeneity was estimated by a likelihood ratio test. In the pooled analysis, Cox proportional-hazards models were used to estimate HRs and 95% CIs for pancreas cancer mortality in relation to BMI. The proportional hazards assumption was tested using Schoenfeld residuals..

In the absence of between-study heterogeneity, we present the results from the pooled analysis. The multivariable analyses were adjusted for known risk factors for pancreatic cancer, including age, smoking, and history of diabetes.

Given the differences in genetic background and lifestyle factors as well as pancreas cancer rates, separate analyses were performed for the East Asian population (Chinese, Japanese and Korean) and South Asian population (Indian and Bangladeshi populations). Results are presented for men and women combined, as well as separately. We show results only for all men and women for the South Asian cohorts because they had a short follow-up period and a very small number of pancreas cancer deaths (31 of all 1489 deaths).

In addition, we conducted analyses stratified by age (<55 years, ≥55 years), smoking status (never, former, current), and history of diabetes (yes, no) to examine whether these factors modified the associations between BMI and risk of pancreas cancer mortality. To examine the significance of interaction, we divided the subjects into two BMI groups: <18.5 and ≥18.5, and then generated a cross-product term in the model. We used a likelihood ratio to test the statistical significance of interaction. As a sensitivity analysis, we also excluded all deaths occurring in the first 3 years of follow-up to address the possibility that BMI variation was the result of disease rather than vice versa.

All analyses were performed using R (version 2.11.1). All statistical tests were 2-sided.

Results

Table 1 presents characteristics of the participating cohorts in the ACC. The mean follow-up period ranged from 3.1 to 22.0 years and the mean age at entry from 36.8 to 59.5 years old. Mean BMI ranged from 19.9 to 23.7. Of 1489 pancreas cancer deaths, 1458 (98%) were observed in East Asia.

Table 1.

Characteristics of the participating cohorts in the Asia Cohort Consortium

Cohort Cohort size at baseline Period of enrollment (yrs) Mean follow-up period (Yrs) Age at entry (Yrs) BMI Female (%) Ever smokers (%) Pancreatic cancer deaths
East Asia
Japan
 JPHC1 41,718 1990–1992 14.4 49.5±5.9 23.6±3.0 51.8 40.4 98
 JPHC2 54,195 1992–1995 11.5 54.1±8.8 23.5±3.1 52.3 40.2 153
 JACC 61,835 1988–1990 12.7 56.7±10.0 22.8±2.9 56.4 37.9 238
 Miyagi Cohort Study 38,027 1990 12.7 51.5±7.6 23.6±2.9 45.2 49.7 80
 3 Pref Miyagi 21,155 1984 11.5 56.4±11.2 23.2±3.2 52.8 40.2 71
 3 Pref Aichi 29,750 1985 11.5 55.9±11.2 22.1±2.9 49.9 50.8 109
 Ohsaki National Health Insurance Cohort Study 39,782 1995 10.0 59.5±10.4 23.5±3.1 46.7 48.7 145
 RERF 47,513 1963 – 1993 22.0 51.9±13.6 22.0±3.4 59.1 44.4 370
Mainland China
 SWHS 73,258 2001–2006 8.6 52.5±9.1 24.0±3.4 100 2.8 76
 SMHS 61,339 1996–2000 3.1 55.3±9.7 23.7±3.1 0 69.6 27
Taiwan
 CBSCP 23,493 1991–1992 15.3 47.3±10.0 24.0±3.4 49.7 28.8 33
Korea
 KMCC 14,436 1993–2004 6.6 55.5±12.1 23.7±3.2 61.4 36.6 23
 Seoul Male Cohort 13,732 1992 – 1993 14.7 49.2±5.2 23.4±2.4 0 77.3 35

South Asia
India
 Mumbai Cohort Study 143,401 1991–1997 5.2 50.7±11.1 22.5±4.0 40.2 18.8 15
 TOCS 125,651 1995–2002 7.5 49.3±12.2 22±3.9 61.4 23.4 16
Bangladesh
 HEALS 10,257 2000–2002 6.6 36.8±9.9 19.9±3.1 58.3 33.9 0

Total 799,542 1489

JPHC, Japanese Public Health Center-based Prospective Study, JACC, Japan Collaborative Cohort Study, 3 pref, Three Prefecture Cohort Study, RERF, Radiation Effects Research Foundation Life-span Study, SWHS, Shanghai Women’s Health Study, SMHS, Shanghai Men’s Health Study CBSCP, Community-based Cancer Screening Project, KMCC, The Korean Multi-Center Cancer Cohort, TOCS, Trivandrum Oral Cancer Screening, HEALS, Health Effects of Arsenic Longitudinal Study, BMI, body mass index

Plus minus values are mean±standard deviation

Table 2 shows the HRs and 95% CIs for pancreas cancer deaths in relation to BMI categories among all Asians, East Asians, and South Asians. In all Asians and East Asians, there were no statistically significant associations between BMI and the risk of death from pancreas cancer in either men or women. In South Asians, those both underweight and overweight were at increased risk of death from pancreas cancer; individuals with a BMI of 27.5–29.9 had 4.9-fold increased risk compared with those with a BMI of 22.5–24.9.

Table 2.

Associations between BMI and the risk of death from pancreas cancer in Asian populations

BMI
<18.5 18.5–19.9 20.0–22.4 22.5–24.9 25.0–27.4 27.5–29.9 ≥30
All Asians
Men and women
 No of deaths 116 130 432 454 232 89 36
 HR1 (95%CI) 0.99 (0.80– 1.22) 0.75 (0.62– 0.92) 0.91 (0.80– 1.04) 1.00 0.93 (0.79– 1.09) 1.04 (0.82– 1.30) 0.99 (0.70– 1.39)
 HR2 (95%CI) 1.04 (0.84–1.30) 0.82 (0.67– 1.00) 0.91 (0.80– 1.05) 1.00 0.95 (0.80– 1.11) 1.01 (0.80– 1.29) 0.96 (0.67– 1.37)
Women
 No of deaths 53 59 174 213 129 52 28
 HR1 (95%CI) 0.82 (0.61– 1.12) 0.72 (0.54– 0.97) 0.78 (0.63– 0.95) 1.00 0.98 (0.78– 1.22) 0.99 (0.73– 1.35) 1.09 (0.73– 1.61)
 HR2 (95%CI) 0.89 (0.64– 1.24) 0.85 (0.63– 1.15) 0.78 (0.63– 0.96) 1.00 1.01 (0.81– 1.27) 1.02 (0.74– 1.39) 1.09 (0.72– 1.65)
Men
 No of deaths 63 71 258 241 103 37 8
 HR1 (95%CI) 1.18 (0.89– 1.57) 0.79 (0.61– 1.04) 1.04 (0.87– 1.24) 1.00 0.86 (0.68– 1.08) 1.06 (0.75– 1.50) 0.71 (0.35– 1.43)
 HR2 (95%CI) 1.20 (0.90– 1.61) 0.80 (0.61– 1.05) 1.03 (0.86– 1.24) 1.00 0.87 (0.69– 1.10) 0.99 (0.69– 1.42) 0.64 (0.30– 1.35)

East Asia
Men and Women
 No of deaths 108 127 423 450 228 86 36
 HR1 (95%CI) 0.97(0.78–1.20) 0.75(0.62–0.92) 0.90(0.79–1.03) 1.00 0.92(0.78–1.08) 1.01(0.80–1.27) 1.00(0.71–1.41)
 HR2 (95%CI) 1.03 (0.82–1.29) 0.81(0.66–1.00) 0.90 (0.79–1.04) 1.00 0.93 (0.79–1.10) 0.98(0.77–1.25) 0.97(0.68–1.38)
Women
 No of deaths 53 57 174 212 128 52 28
 HR1 (95%CI) 0.83(0.60–1.13) 0.70(0.52–0.94) 0.78(0.64–0.95) 1.00 0.97(0.78–1.21) 1.00(0.74–1.36) 1.10(0.74–1.63)
 HR2 (95%CI) 0.90(0.64–1.25) 0.82(0.61–1.12) 0.78(0.63–0.97) 1.00 1.00(0.80–1.26) 1.02(0.74–1.39) 1.09(0.72–1.65)
Men
 No of deaths 55 70 249 238 100 34 8
 HR1 (95%CI) 1.14(0.84–1.54) 0.81(0.62–1.06) 1.02(0.85–1.22) 1.00 0.84(0.67–1.07) 1.00(0.10–1.43) 0.73(0.36–1.48)
 HR2 (95%CI) 1.18(0.87–1.60) 0.81(0.62–1.07) 1.02(0.85–1.22) 1.00 0.85(0.68–1.08) 0.92(0.63–1.34) 0.66(0.31–1.40)

South Asia
Men andn women
 No of deaths 8 3 9 4 4 3 0
 HR1 (95%CI) 2.09(0.62–6.98) 1.12(0.25–5.00) 1.84(0.57–5.97) 1.00 1.82(0.45–7.27) 3.57(0.80–16.01)
 HR2 (95%CI) 2.27(0.57–8.85) 1.42(0.28–7.01) 2.12(0.56–7.99) 1.00 2.45(0.54–11.00) 4.93(0.99–24.48)

HR: hazard ratio; CI: confidence interval

HR1: Adjusted for age, sex and cohort

HR2: Adjusted for age, sex, cohort, cigarette smoking and history of type II diabetes

Table 3 shows the results of subgroup analyses stratified by age, smoking status, and diabetes among East Asians. There were no associations between obesity and the risk of death from pancreas cancer in current smokers, ex-smokers, or non-smokers. In planned analyses stratified by diabetes, we observed a statistically significantly increased risk of death associated with low BMI (BMI <18.5) among individuals with a history of diabetes; the HR was 2.01 (95%CI: 1.01–4.00) (p for interaction=0.07). There were no associations between BMI and risk of death from pancreas cancer among those without a history of diabetes. For both East Asian men and women, the risk estimates remained unchanged after excluding deaths that occurred within the first 3 years of follow-up. Additional adjustment for marital status and education in the multivariate model did not materially alter the results (data not shown).

Table 3.

Hazard ratios for pancreas cancer deaths in relation to BMI in East Asians according to age, smoking status and history of diabetes

BMI
<18.5 18.5–19.9 20.0–22.4 22.5–24.9 25.0–27.4 27.5–29.9 ≥30
Ages<55
 No. of deaths 30 32 125 131 63 29 7
 HR (95%CI) 1.12(0.73–1.73) 0.68(0.45–1.01) 0.92(0.71–1.19) 1.00 0.91(0.67–1.25) 1.22(0.80–1.87) 0.73(0.32–1.67)
Ages ≧55
 No of deaths 78 95 298 319 165 57 29
 HR (95%CI) 1.01(0.78–1.32) 0.88(0.70–1.12) 0.91(0.77–1.07) 1.00 0.93(0.77–1.13) 0.87(0.65–1.17) 1.01(0.68–1.50)

Nonsmokers
 No. of deaths 57 58 185 220 131 55 26
 HR (95%CI) 1.15(0.84–1.59) 0.90(0.67–1.21) 0.84(0.68–1.04) 1.00 1.00(0.80–1.25) 1.08(0.79–1.47) 1.09(0.71–1.67)
Ex-smokers
 No. of deaths 12 6 65 60 28 6 3
 HR (95%CI) 1.34(0.69–2.60) 0.36(0.14–0.90) 1.28(0.89–1.84) 1.00 0.90(0.57–1.41) 0.63(0.27–1.47) 0.67(0.16–2.77)
Current smokers
 No of deaths 39 63 173 170 69 25 7
 HR (95%CI) 0.83(0.58–1.19) 0.80(0.59–1.08) 0.86(0.69–1.06) 1.00 0.87(0.65–1.15) 0.97(0.63–1.50) 0.80(0.37–1.70)

Individulas without history of diabetes
 No. of deaths 87 111 347 384 194 72 32
 HR (95%CI) 0.96(0.76–1.22) 0.78(0.63–0.97) 0.87(0.75–1.00) 1.00 0.92(0.77–1.09) 1.00(0.77–1.28) 1.07(0.75–1.54)
Individulas with history of diabetes
 No. of deaths 11 11 40 35 24 8 1
 HR (95%CI) 2.01(1.01–4.00) 1.24(0.63–2.45) 1.33(0.84–2.10) 1.00 1.11(0.66–1.87) 0.97(0.45–2.09) 0.26(0.04–1.90)

Excluding deaths within the first 3 years of follow-up
 No. of deaths 82 109 368 391 204 75 29
 HR (95%CI) 0.84(0.65–1.09) 0.77(0.62–0.96) 0.88(0.76–1.02) 1.00 0.97(0.82–1.16) 1.01(0.78–1.31) 0.90(0.60–1.34)

HR: hazard ratio; CI: confidence interval

Men and women combined

HR: Adjusted for age, sex, cohort, cigarette smoking and history of type II diabetes

Discussion

In this pooled analysis of 799,542 Asian men and women, we found no overall associations between BMI and the risk of death from pancreas cancer in Asian populations. The findings were also null when we restricted the analyses to men and women who had never smoked or those who had no history of type-II diabetes.

Epidemiologic research has been inconclusive regarding the association between BMI and pancreas cancer in Asians. No statistically significant increase in pancreas cancer risk among the obese was observed in the JACC study [22] and the JPHC study [23], two representative Japanese cohort studies and also cohorts participating in the ACC. In another cohort study conducted in Miyagi Prefecture [24], the obesity-pancreas cancer associations could not be quantified because no deaths had occurred in the BMI category of 30 or more. In a prospective study of over 1 million Koreans, pancreatic cancer risk was statistically significantly elevated in women who were either overweight or obese; however, no association was observed in men [25]. In China, although a previous case-control study had suggested a positive association between BMI and pancreas cancer [32], no prospective cohort data have been available to examine this association. The available data, together with findings in the present study, do not support a role for obesity in the risk of pancreas cancer in East Asians. It is worth noting that the individual Asian cohort studies may have been underpowered to detect a small-to-moderate association due to very few individuals in the obese category. We, therefore, sought to overcome this limitation by pooling the data from 16 cohort studies across Asian countries, the majority of which are from East Asia; the results remain null. Consistent with our results, a pooled analysis of 424,519 participants in the Asia-Pacific Cohort Studies Collaboration found no increase in pancreas cancer risk among obese Asians [33]. For South Asians, although the results suggested an increase in risk among underweight and overweight individuals, the number of pancreas cancer deaths was too small to draw any firm conclusions. Given a potentially high level of misclassifications for pancreas cancer mortality, improving diagnostic accuracy is also an important issue in further studies. With extended follow-up and improved outcome ascertainment, further studies in these cohorts with a larger sample will be able to better quantify the association in South Asians.

There are several potential explanations for the null findings on the BMI-pancreas cancer association in Asian populations. The main reason may be the very small proportion of obese people in Asia. Although this pooled analysis included the largest number of Asians, the obese accounted for only 2.5%, much lower than that (approximately 16–20%) in the pooled analyses of Western cohort studies [14, 15]. The null findings could also be due to the differences in body fat distribution, in genetic predisposition to obesity, and in lifestyle factors between Caucasians and Asians [21, 34]. For example, diet is thought to play an important role in the development of pancreas cancer and the interaction of BMI with diet is possibly different between Caucasians and Asians. This issue needs to be addressed in additional studies. Finally, we could not exclude the possibility that some heterogeneity may still exist among the participating cohorts, although data were harmonized at the coordinating center using a standardized method and we found no between-study heterogeneity.

An interesting finding is that individuals who had a history of diabetes and a lower BMI were at 2-fold increased risk for pancreas cancer. Longstanding diabetes has been linked to an increased risk of pancreas cancer in numerous epidemiologic studies, including those from Japan and Korea [4]. Because insulin resistance and hyperinsulinemia that characterize diabetes can be either causes or consequences of pancreas cancer, it is difficult to disentangle the complex association among BMI, diabetes, and pancreas cancer risk. A recent pooled analysis of ACC cohort studies demonstrated that both low BMI and high BMI are associated with increased risk of all-cause mortality in all East Asian populations [26]. There is also evidence suggesting that Asian people are more susceptible to insulin resistance at a lesser degree of obesity than people of European descent [34]. This might increase the likelihood that, indeed, low BMI and diabetes act synergistically in the development of pancreatic cancer in this population. However, this was a subgroup analysis and chance remains a plausible explanation of the results.

Our study has several strengths. With the largest number of diverse Asian populations included in this pooled analysis, we were able to examine the association of pancreas cancer mortality with narrow BMI categories. In addition, we performed analyses stratified by sex, age, smoking status, and diabetes to examine whether these factors modify or confound the BMI-pancreas cancer association.

We recognize several limitations of our study. First, misclassification derived from collection of exposure data may be a concern. The validity of self-reported BMI data can be questioned in part of East Asian cohorts. However, we consider this may not seriously bias the results because our previous study has shown a similar pattern of association between BMI and death from any cause when either self-reported or measured data on height and weight were used [26]. Some non-differential misclassification may be present because BMI was not updated during the follow-up period. Second, information on pancreas cancer mortality was confirmed solely by death certificates in the majority of the ACC participating cohorts. This may have led to some misclassification of outcome. Third, few participating cohorts included in this pooled analysis measured waist circumference or waist/hip ratio, which may be a better index for adiposity than BMI in the elderly [35]. Cohort studies have shown that waist circumference and waist-hip ratio are associated with pancreas cancer risk in Caucasians [36, 37]; however, very few studies are available for Asians. A comprehensive measure of adiposity will further our understanding of the role of obesity in the development of pancreas cancer.

In summary, unlike the findings in Western countries, we found no overall association between BMI and the risk of death from pancreas cancer in the pooled analysis of Asian men and women. With the increasing prevalence of overweight and obesity and type-II diabetes in Asians [38], additional studies will be needed to further address this possible association.

Acknowledgments

Source of funding

This work was supported by the National Cancer Institute at the National Institutes of Health (R03CA150038) and by the Fred Hutchinson Cancer Research Center.

The original cohorts were supported by: Japan Public Health Center-based Study I & II (JPHC I & II): 1) Management Expenses Grants from the Government to the National Cancer Center; 2) Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan; 3) Grant-in-Aid for the Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare, Japan; Japan Collaborative Cohort Study (JACC): Grant-in-Aid for the Scientific Research from the Ministry of Education, Culture, Sports, Science & Technology, Japan; the Three Prefecture Cohort Study Aichi (3-Pref Aichi) and the three Prefecture Cohort Study Miyagi (3-Pref Miyagi): Research grant from the Ministry of Health, Labour, and Welfare, and the Ministry of Education, Culture, Sports, Science & Technology, Japan; The Miyagi Cohort Study (Miyagi); Research grant from the Ministry of Health, Labour, and Welfare, Japan; The Ohsaki National Health Insurance Cohort Study (Ohsaki): Research grant from Ministry of Health, Labour, and Welfare, Japan; Radiation Effects Research Foundation (RERF): The Radiation Effects Research Foundation (RERF), Hiroshima and Nagasaki, Japan is a private, non-profit foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the U.S. Department of Energy (DOE), the latter in part through DOE Award DE-HS0000031 to the National Academy of Sciences. This publication was supported by RERF Research Protocol RP A3-10. The views of the authors do not necessarily reflect those of the two governments; Shanghai Women’s Health Study (SWHS): United States Public Health Service grant (R37CA070867); Shanghai Men’s Health Study (SMHS): United States Public Health Service grant (R01 CA082729); the Community-Based Cancer Screening Project (CBCSP): National Science Council and Department of Health, Taiwan; the Korea Multi-center Cancer Cohort (KMCC): Ministry of Education, Science and Technology, Korea (2009-0087452), National Research Foundation of Korea (2009-0087452); Seoul Male Cohort: the National R&D Program for Cancer Control, Ministry of Health&Welfare, Republic of Korea (0520160-1); the Mumbai Cohort Study (MCS): International Agency for Research on Cancer, Clinical Trials Service Unit/Oxford University, World Health Organization; the Health Effects of Arsenic Longitudinal Study (HEALS): National Institutes for Health (P42ES010349, R01CA102484, R01CA107431); the Trivandrum Oral Cancer Screening Trial (TOCS): Associations for International Cancer Research, St Andrews, UK, and Cancer Research UK.

Footnotes

Conflict of interest:

The authors have declared no conflict of interest.

References

  • 1.Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–1427. doi: 10.1093/jnci/dji289. [DOI] [PubMed] [Google Scholar]
  • 2.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. [Google Scholar]
  • 3.Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393:535–545. doi: 10.1007/s00423-007-0266-2. [DOI] [PubMed] [Google Scholar]
  • 4.Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928–1937. doi: 10.1016/j.ejca.2011.03.003. [DOI] [PubMed] [Google Scholar]
  • 5.Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591. doi: 10.1038/nrc1408. [DOI] [PubMed] [Google Scholar]
  • 6.Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638. doi: 10.1056/NEJMoa021423. [DOI] [PubMed] [Google Scholar]
  • 7.Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer. 2005;93:1062–1067. doi: 10.1038/sj.bjc.6602819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286:921–929. doi: 10.1001/jama.286.8.921. [DOI] [PubMed] [Google Scholar]
  • 9.Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer. 2007;120:1993–1998. doi: 10.1002/ijc.22535. [DOI] [PubMed] [Google Scholar]
  • 10.Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23:843–852. doi: 10.1093/annonc/mdr398. [DOI] [PubMed] [Google Scholar]
  • 11.Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer. 2003;89:519–523. doi: 10.1038/sj.bjc.6601140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578. doi: 10.1016/S0140-6736(08)60269-X. [DOI] [PubMed] [Google Scholar]
  • 13.Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) Arch Intern Med. 2010;170:791–802. doi: 10.1001/archinternmed.2010.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jiao L, Berrington de Gonzalez A, Hartge P, Pfeiffer RM, Park Y, Freedman DM, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control. 2010;21:1305–1314. doi: 10.1007/s10552-010-9558-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer. 2011;129:1708–1717. doi: 10.1002/ijc.25794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283:2552–2558. doi: 10.1001/jama.283.19.2552. [DOI] [PubMed] [Google Scholar]
  • 17.Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294:2872–2878. doi: 10.1001/jama.294.22.2872. [DOI] [PubMed] [Google Scholar]
  • 18.Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194–202. doi: 10.1001/jama.293.2.194. [DOI] [PubMed] [Google Scholar]
  • 19.Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886–895. doi: 10.1038/nrc3174. [DOI] [PubMed] [Google Scholar]
  • 20.World Research Fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007. [Google Scholar]
  • 21.Wen W, Cho YS, Zheng W, Dorajoo R, Kato N, Qi L, et al. Meta-analysis identifies common variants associated with body mass index in East Asians. Nat Genet. 2012;44:307–311. doi: 10.1038/ng.1087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lin Y, Kikuchi S, Tamakoshi A, Yagyu K, Obata Y, Inaba Y, et al. Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer. 2007;120:2665–2671. doi: 10.1002/ijc.22614. [DOI] [PubMed] [Google Scholar]
  • 23.Luo J, Iwasaki M, Inoue M, Sasazuki S, Otani T, Ye W, et al. Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan--the JPHC study. Cancer Causes Control. 2007;18:603–612. doi: 10.1007/s10552-007-9002-z. [DOI] [PubMed] [Google Scholar]
  • 24.Kuriyama S, Tsubono Y, Hozawa A, Shimazu T, Suzuki Y, Koizumi Y, et al. Obesity and risk of cancer in Japan. Int J Cancer. 2005;113:148–157. doi: 10.1002/ijc.20529. [DOI] [PubMed] [Google Scholar]
  • 25.Jee SH, Yun JE, Park EJ, Cho ER, Park IS, Sull JW, et al. Body mass index and cancer risk in Korean men and women. Int J Cancer. 2008;123:1892–1896. doi: 10.1002/ijc.23719. [DOI] [PubMed] [Google Scholar]
  • 26.Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364:719–729. doi: 10.1056/NEJMoa1010679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rolland B, Smith BR, Potter JD. Coordinating centers in cancer epidemiology research: the Asia Cohort Consortium coordinating center. Cancer Epidemiol Biomarkers Prev. 2011;20:2115–2119. doi: 10.1158/1055-9965.EPI-11-0391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 29.Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355:779–787. doi: 10.1056/NEJMoa054017. [DOI] [PubMed] [Google Scholar]
  • 30.Sasazuki S, Inoue M, Tsuji I, Sugawara Y, Tamakoshi A, Matsuo K, et al. Body mass index and mortality from all causes and major causes in Japanese: results of a pooled analysis of 7 large-scale cohort studies. J Epidemiol. 2011;21:417–430. doi: 10.2188/jea.JE20100180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chen Z, Yang G, Offer A, Zhou M, Smith M, Peto R, et al. Body mass index and mortality in China: a 15-year prospective study of 220 000 men. Int J Epidemiol. 2012;41:472–481. doi: 10.1093/ije/dyr208. [DOI] [PubMed] [Google Scholar]
  • 32.Ji BT, Hatch MC, Chow WH, McLaughlin JK, Dai Q, Howe GR, et al. Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Int J Cancer. 1996;66:432–437. doi: 10.1002/(SICI)1097-0215(19960516)66:4<432::AID-IJC4>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • 33.Parr CL, Batty GD, Lam TH, Barzi F, Fang X, Ho SC, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol. 2010;11:741–752. doi: 10.1016/S1470-2045(10)70141-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas. 2010;65:315–319. doi: 10.1016/j.maturitas.2009.12.012. [DOI] [PubMed] [Google Scholar]
  • 35.Biggs ML, Mukamal KJ, Luchsinger JA, Ix JH, Carnethon MR, Newman AB, et al. Association between adiposity in midlife and older age and risk of diabetes in older adults. JAMA. 2010;303:2504–2512. doi: 10.1001/jama.2010.843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Stolzenberg-Solomon RZ, Adams K, Leitzmann M, Schairer C, Michaud DS, Hollenbeck A, et al. Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. Am J Epidemiol. 2008;167:586–597. doi: 10.1093/aje/kwm361. [DOI] [PubMed] [Google Scholar]
  • 37.Berrington de González A, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjaer J, Tjønneland A, et al. Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2006;15:879–885. doi: 10.1158/1055-9965.EPI-05-0800. [DOI] [PubMed] [Google Scholar]
  • 38.Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681–1688. doi: 10.1016/S0140-6736(06)69703-1. [DOI] [PubMed] [Google Scholar]

RESOURCES